BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

BrainsWay (BWAY) presented real-world Deep TMS data in 462 comorbid PTSD+MDD patients: 83.5% achieved PTSD response (≥50% PCL-5 reduction) with a 52% mean PCL-5 improvement, and depression outcomes improved with a 66.6% response rate, 27.3% remission, and a 50% mean PHQ-9 reduction. The company emphasizes the results are retrospective and still subject to peer review, noting Deep TMS is not yet FDA-cleared for PTSD/comorbid PTSD+MDD.

Analysis

This is more a commercial de-risking event than a regulatory one. In practice, the value is that it gives the sales force a larger, harder-to-ignore reimbursement narrative for a high-need psychiatric subgroup; the near-term upside is in conversion rates at existing clinics and potentially higher treatment utilization, not in a step-change in product approval.

The second-order effect is competitive: if providers start viewing Deep TMS as a credible option for treatment-resistant PTSD/depression overlap, BWAY can pressure smaller TMS competitors on differentiation and pricing discipline. But the same data also risks being overread by investors — without a prospective trial or label expansion, payers may treat this as hypothesis-generating, so any revenue benefit likely lags by quarters and shows up first in bookings, installed base utilization, and payer conversations rather than reported sales.

The main contrarian point is that the market may be extrapolating too much from a retrospective dataset. The fastest reversal would be a lack of follow-through in clinic-level utilization, no improvement in reimbursement coverage, or an inability to translate conference momentum into sequential revenue acceleration over the next 1-2 quarters. Longer term, the real optionality is an FDA or guideline path in PTSD; absent that, this is evidence accumulation, not a rerating catalyst on its own.

Key Decisions for Investors

• Buy BWAY only on weakness for a 1-3 month event-driven trade; the thesis is modest multiple support from better evidence, with upside capped unless utilization and bookings accelerate. Falsifier: next quarterly report fails to show higher treatment sessions per system or expanding installed base.
• Pair long BWAY / short STIM over 3-6 months as a relative-quality expression on differentiated clinical evidence and commercial execution. Risk/reward improves if BWAY sees better provider adoption while STIM remains a more generic TMS exposure.
• Do not initiate an options chase here; implied upside is likely to decay unless management can convert this into a prospective study, payer coverage win, or new indication pathway. Reassess only after the next earnings call or trial update.
• Set an alert for any FDA, payer, or guideline development in PTSD/depression comorbidity; that is the real 6-18 month rerating catalyst. Without that, treat this as a sales-enablement story rather than a fundamental step-change.